Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? | Zendy

Yuanhui Zhang | Zendy; Rozalina G. McCoy | Zendy; Jennifer Mason | Zendy; Steven A. Smith | Zendy; Nilay D. Shah | Zendy; Brian T. Denton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?

Author(s) -

Yuanhui Zhang,

Rozalina G. McCoy,

Jennifer Mason,

Steven A. Smith,

Nilay D. Shah,

Brian T. Denton

Publication year - 2014

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc13-1901

Subject(s) - medicine , glycemic , type 2 diabetes , metformin , diabetes mellitus , population , sulfonylurea , insulin , endocrinology , environmental health

While metformin is generally accepted as the first-line agent in treatment of type 2 diabetes, there are insufficient evidence and extensive debate about the best second-line agent. We aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research